357 related articles for article (PubMed ID: 14622169)
1. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
Hurley MJ; Mash DC; Jenner P
Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
[TBL] [Abstract][Full Text] [Related]
2. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Aubert I; Guigoni C; Håkansson K; Li Q; Dovero S; Barthe N; Bioulac BH; Gross CE; Fisone G; Bloch B; Bezard E
Ann Neurol; 2005 Jan; 57(1):17-26. PubMed ID: 15514976
[TBL] [Abstract][Full Text] [Related]
3. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
4. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use.
Court JA; Lloyd S; Thomas N; Piggott MA; Marshall EF; Morris CM; Lamb H; Perry RH; Johnson M; Perry EK
Neuroscience; 1998 Nov; 87(1):63-78. PubMed ID: 9722142
[TBL] [Abstract][Full Text] [Related]
5. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Gross CE; Ravenscroft P; Dovero S; Jaber M; Bioulac B; Bezard E
J Neurochem; 2003 Mar; 84(6):1246-55. PubMed ID: 12614325
[TBL] [Abstract][Full Text] [Related]
6. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
[TBL] [Abstract][Full Text] [Related]
7. ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia.
Galter D; Buervenich S; Carmine A; Anvret M; Olson L
Neurobiol Dis; 2003 Dec; 14(3):637-47. PubMed ID: 14678778
[TBL] [Abstract][Full Text] [Related]
8. Liposomal Form of L-Dopa and SH-Sy5y Cell-Derived Exosomes Modulate the Tyrosine Hydroxylase/Dopamine Receptor D2 Signaling Pathway in Parkinson's Rat Models.
Zarrin P; Dehghani Ashkezari M; Seifati SM
J Mol Neurosci; 2021 Dec; 71(12):2583-2592. PubMed ID: 34125397
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias.
Cheshire P; Ayton S; Bertram KL; Ling H; Li A; McLean C; Halliday GM; O'Sullivan SS; Revesz T; Finkelstein DI; Storey E; Williams DR
Mov Disord; 2015 May; 30(6):796-804. PubMed ID: 25649148
[TBL] [Abstract][Full Text] [Related]
11. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
Quik M; Police S; He L; Di Monte DA; Langston JW
Neuroscience; 2000; 98(2):263-73. PubMed ID: 10854757
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Costa D; Perry RH; Perry EK
Neuroscience; 1999 May; 90(2):433-45. PubMed ID: 10215149
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of dopamine receptors in cholinergic motoneurons of the hypoglossal nucleus in a 6-OHDA-induced Parkinson's disease rat model.
Zhou L; Wang ZY; Lian H; Song HY; Zhang YM; Zhang XL; Fan RF; Zheng LF; Zhu JX
Biochem Biophys Res Commun; 2014 Sep; 452(3):560-6. PubMed ID: 25172664
[TBL] [Abstract][Full Text] [Related]
15. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.
Jenner P
Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S3-7. PubMed ID: 15180131
[TBL] [Abstract][Full Text] [Related]
17. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors.
Joyce JN; Ryoo HL; Beach TB; Caviness JN; Stacy M; Gurevich EV; Reiser M; Adler CH
Brain Res; 2002 Nov; 955(1-2):138-52. PubMed ID: 12419530
[TBL] [Abstract][Full Text] [Related]
18. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
[TBL] [Abstract][Full Text] [Related]
19. Elevated D3 dopamine receptor mRNA in dopaminergic and dopaminoceptive regions of the rat brain in response to morphine.
Spangler R; Goddard NL; Avena NM; Hoebel BG; Leibowitz SF
Brain Res Mol Brain Res; 2003 Mar; 111(1-2):74-83. PubMed ID: 12654507
[TBL] [Abstract][Full Text] [Related]
20. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
St-Hilaire M; Landry E; Lévesque D; Rouillard C
Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
